## Core Concept
The incretin effect refers to the phenomenon where oral glucose ingestion leads to a greater insulin secretory response compared to intravenous glucose administration. This effect is primarily mediated by incretin hormones, such as **GLP-1 (Glucagon-like peptide-1)** and **GIP (Glucose-dependent insulinotropic polypeptide)**. These hormones enhance glucose-dependent insulin secretion, suppress glucagon release, and have other beneficial effects on glucose metabolism.

## Why the Correct Answer is Right
The correct answer, **Exenatide**, is a medication that mimics the action of the incretin hormone **GLP-1**. It is a GLP-1 receptor agonist used in the treatment of type 2 diabetes mellitus. By activating GLP-1 receptors, exenatide enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. This pharmacological profile makes exenatide an incretin-like substance.

## Why Each Wrong Option is Incorrect
* **Option A:** This option is blank and does not provide a valid choice for analysis.
* **Option B:** This option is also blank and cannot be evaluated.
* **Option D:** Similarly, this option is blank and lacks the necessary information for assessment.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **GLP-1 receptor agonists**, such as exenatide, liraglutide, and others, are used not only for their glucose-lowering effects but also for their potential benefits on weight management and cardiovascular outcomes. These agents are particularly useful in patients with type 2 diabetes who require additional glucose control beyond what can be achieved with oral medications.

## Correct Answer Line
**Correct Answer: C. Exenatide**